BioMarin Pharmaceutical (NASDAQ:BMRN) Upgraded at UBS Group

UBS Group upgraded shares of BioMarin Pharmaceutical (NASDAQ:BMRN) to a strong-buy rating in a research note released on Wednesday morning,Zacks reports.

Several other research firms have also commented on BMRN. Morgan Stanley lifted their price target on shares of BioMarin Pharmaceutical from $119.00 to $124.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. BMO Capital Markets reiterated an “outperform” rating on shares of BioMarin Pharmaceutical in a report on Wednesday, September 16th. Raymond James Financial upgraded BioMarin Pharmaceutical from an “outperform” rating to a “strong-buy” rating and set a $109.00 price objective for the company in a research report on Monday, October 12th. William Blair raised BioMarin Pharmaceutical to a “hold” rating in a research note on Wednesday, September 23rd. Finally, Canaccord Genuity Group lifted their target price on BioMarin Pharmaceutical from $111.00 to $114.00 and gave the company a “buy” rating in a research report on Monday, August 10th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, BioMarin Pharmaceutical presently has an average rating of “Moderate Buy” and an average target price of $88.87.

BioMarin Pharmaceutical Trading Down 2.4%

BioMarin Pharmaceutical stock traded down $1.37 during midday trading on Wednesday, hitting $54.68. 2,627,811 shares of the stock were exchanged, compared to its average volume of 2,366,833. BioMarin Pharmaceutical has a fifty-two week low of $49.26 and a fifty-two week high of $70.98. The stock has a market capitalization of $10.58 billion, a price-to-earnings ratio of 147.78, a PEG ratio of 0.39 and a beta of 0.22. The stock’s 50-day simple moving average is $63.01 and its 200 day simple moving average is $58.66. The company has a current ratio of 2.39, a quick ratio of 1.32 and a debt-to-equity ratio of 0.56.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.25. The company had revenue of $989.71 million for the quarter, compared to the consensus estimate of $932.03 million. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. BioMarin Pharmaceutical’s quarterly revenue was up 20.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.44 earnings per share. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. On average, equities analysts anticipate that BioMarin Pharmaceutical will post 4.10 EPS for the current year.

Institutional Investors Weigh In On BioMarin Pharmaceutical

A number of institutional investors have recently made changes to their positions in the stock. Mather Group LLC. lifted its holdings in shares of BioMarin Pharmaceutical by 71.0% in the 3rd quarter. Mather Group LLC. now owns 2,337 shares of the biotechnology company’s stock worth $140,000 after acquiring an additional 970 shares during the last quarter. Sanders Morris Harris LLC purchased a new position in shares of BioMarin Pharmaceutical during the 3rd quarter worth approximately $240,000. Wedmont Private Capital acquired a new stake in BioMarin Pharmaceutical in the 3rd quarter valued at approximately $222,000. GAMMA Investing LLC increased its holdings in BioMarin Pharmaceutical by 50.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,642 shares of the biotechnology company’s stock valued at $219,000 after purchasing an additional 1,220 shares during the last quarter. Finally, Farther Finance Advisors LLC increased its holdings in BioMarin Pharmaceutical by 7.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 8,489 shares of the biotechnology company’s stock valued at $509,000 after purchasing an additional 618 shares during the last quarter. 98.71% of the stock is currently owned by institutional investors and hedge funds.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company that develops and commercializes therapies for rare and serious genetic diseases. The company focuses on conditions with limited treatment options, using approaches that include enzyme replacement therapy, small-molecule medicines, biologics and gene therapy.

Its products include Vimizim for mucopolysaccharidosis type IV A, Naglazyme for mucopolysaccharidosis type VI, Brineura for CLN2 disease, Palynziq and Kuvan for phenylketonuria, and Voxzogo for children with achondroplasia and open growth plates.